{"prompt": "['2017N323364_0', 'CONFIDENTIAL', '2019N398531_00', '207626', 'Participants that permanently discontinue study treatment are not required to withdraw', 'from the study. If for any reason a participant must permanently discontinue study', 'treatment, every effort should be made by the Investigator/staff to keep the participant in', 'the study and complete all remaining protocol specified clinic visits However, a', 'participant may voluntarily withdraw from participation in this study at any time. The', 'Investigator may also, at his or her discretion, withdraw a participant from further study', 'participation. Participants who are withdrawn from the study will not be replaced.', 'A participant will be considered to have completed the study when they have completed', 'all phases of the study including screening, run-in, the randomised treatment phase, and', 'safety follow-up.', 'Number of Participants:', 'Approximately 848 participants with advanced COPD will enter the run-in period, in', 'order to randomise approximately 780 participants, in order to achieve an estimated 702', 'evaluble participants.', 'Approximately 100 centres globally will be required to recruit the study.', 'Treatment Groups and Duration:', 'Participants who meet all the eligibility criteria and who have successfully completed all', 'protocol procedures at Screening will enter the 4-week run-in period and will take open-', 'label tiotropium 18 mcg via the HandiHaler once daily plus placebo via the', 'ELLIPTA Following the run-in period, eligible participants will be randomised (1:1) to', 'one of the following double-blind, double-dummy treatment groups for 84 days:', 'Either:', 'FF/UMEC/VI 100/62.5/25 mcg via the ELLIPTA once daily in the morning', '+ placebo to match tiotropium via HandiHaler once daily in the morning', 'or,', 'Tiotropium 18 mcg via HandiHaler once daily in the morning', '+ placebo via the ELLIPTA once daily in the morning', 'The ELLIPTA contains 30 doses (FF/UMEC/VI or placebo) and participants will be', 'instructed to administer one dose from their ELLIPTA once daily in the morning.', 'Tiotropium or matching placebo: Contents of 1 capsule (18 mcg) inhaled once daily', 'using HandiHaler device. Note: To ensure drug delivery, two inhalations of the contents', 'of each capsule should be performed.', '15']['2017N323364_0', 'CONFIDENTIAL', '2019N398531_00', '207626', 'Key Elements of Analysis Plan:', 'The primary objective of this study is to compare single inhaler triple therapy', '(FF/UMEC/VI) with tiotropium (TIO) in participants with COPD who have received', 'tiotropium and continue to have symptoms as measured by CAT >10. The primary', 'endpoint is trough FEV1 at Week 12 (Day 85). The primary analysis is the comparison of', 'this endpoint between FF/UMEC/VI and tiotropium.', 'The null hypothesis is that there is no difference between treatment groups.', 'HO: T1 - T2 = 0', 'The alternative hypothesis is there is a difference between treatment groups.', 'H1: T1 - T2 # 0', 'where T1 and T2 are the treatment means for FF/UMEC/VI and TIO, respectively.', 'The primary analyses will be based on the ITT population using only data collected on', 'treatment, the analysis will evaluate the endpoint of trough FEV1 using a mixed model', 'repeated measures (MMRM) analysis, including on-treatment trough FEV1 recorded at', 'each of visits, Day 28, Day 84 and Day 85. The model will include covariates of baseline', 'FEV1, visit, geographical region, treatment and visit by baseline interaction. A visit by', 'treatment interaction term will also be included to allow treatment effects to be estimated', 'at each visit separately. The variance-covariance matrix will be assumed unstructured.', 'Estimated differences between FF/UMEC/VI and tiotropium will be presented together', 'with 95 % confidence intervals (CIs) for the difference and p-values.', 'The details of the statistical analysis methods for the secondary efficacy endpoint will be', 'provided in the Reporting and Analysis Plan (RAP).', '16']\n\n###\n\n", "completion": "END"}